The lentivirus human immunodeficiency virus (HIV) causes AIDS by interacting with a large
number of different cells in the body and escaping the host immune response against it. HIV …

There are 16 approved human immunodeficiency virus type 1 (HIV-1) drugs belonging to
three mechanistic classes: protease inhibitors, nucleoside and nucleotide reverse …

The genetic diversity of human immunodeficiency virus (HIV) is a major concern thought to
impact on immunologic escape and eventual vaccine efficacy. Here, simple and rapid …

Background: The gp120 exterior envelope glycoprotein of HIV-1 binds sequentially to CD4
and chemokine receptors on cells to initiate virus entry. During natural infection, gp120 is a …

The virulence properties of human immunodeficiency virus type 2 (HIV-2) are known to vary
significantly and to range from relative attenuation in certain individuals to high-level …

Since 1989, human immunodeficiency virus type 1 (HIV-1) has spread explosively through
the heterosexual population in Thailand. This epidemic is caused primarily by viruses …

Combination therapy with protease (PR) and reverse transcriptase (RT) inhibitors can
efficiently suppress human immunodeficiency virus (HIV) replication, but the emergence of …

Signature pattern analysis identifies particular sites in amino acid or nucleic acid alignments
of variable sequences that are distinctly representative of a query set of sequences relative …

Human immunodeficiency virus type 1 (HIV-1) sequences were generated from blood and
from brain tissue obtained by stereotactic biopsy from six patients undergoing a diagnostic …

High rates of mutation and replication of human immunodeficiency virus (HIV) allow for the
continuous generation of diverse genetic variants in vivo. Selective pressures within the …